NeuroPace (NPCE) Invested Capital (2020 - 2021)

NeuroPace's (NPCE) quarterly Invested Capital came in at $3.6 million in Q1 2021, up 75.72% quarter-over-quarter from $2.0 million in Q4 2020.

NeuroPace (NPCE) Invested Capital (2020 - 2021) Analysis & Trends

NeuroPace's Invested Capital history runs 2 years deep, the most recent figure standing at $3.6 million for Q1 2021.

  • On a quarterly basis, Invested Capital changed N/A year-over-year to $3.6 million in Q1 2021; TTM through Dec 2021 was $3.6 million, a 75.72% increase from a year earlier, with the FY2020 full-year figure at $2.0 million, changed N/A from the prior year.
  • Invested Capital improved to $3.6 million in Q1 2021 per NPCE's latest filing, from $2.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $3.6 million in Q1 2021 and bottomed at $2.0 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 4.41 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 499.00 Mn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 1.79 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 41.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 1.41 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 7.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - 15.00 Mn
10 NeuroPace 494.96 Mn 440.98 Mn 18.05 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2021 3.59 Mn
Dec 31, 2020 2.04 Mn